Table of Content

1 Cellular Tumor Antigen p53 Market Overview
1.1 Product Overview and Scope of Cellular Tumor Antigen p53
1.2 Cellular Tumor Antigen p53 Segment by Type
1.2.1 Global Cellular Tumor Antigen p53 Market Value Comparison by Type (2024-2034)
1.2.2 COTI-2
1.2.3 D-12PGJ3
1.2.4 APR-246
1.2.5 ATRN-502
1.2.6 Cenersen Sodium
1.2.7 MJ-05
1.2.8 MX-225
1.2.9 Others
1.3 Cellular Tumor Antigen p53 Segment by Application
1.3.1 Global Cellular Tumor Antigen p53 Market Value by Application: (2024-2034)
1.3.2 Ovarian Cancer
1.3.3 Prostate Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Global Cellular Tumor Antigen p53 Market Size Estimates and Forecasts
1.4.1 Global Cellular Tumor Antigen p53 Revenue 2018-2034
1.4.2 Global Cellular Tumor Antigen p53 Sales 2018-2034
1.4.3 Global Cellular Tumor Antigen p53 Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Cellular Tumor Antigen p53 Market Competition by Manufacturers
2.1 Global Cellular Tumor Antigen p53 Sales Market Share by Manufacturers (2018-2024)
2.2 Global Cellular Tumor Antigen p53 Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Cellular Tumor Antigen p53 Average Price by Manufacturers (2018-2024)
2.4 Global Cellular Tumor Antigen p53 Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Cellular Tumor Antigen p53, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cellular Tumor Antigen p53, Product Type & Application
2.7 Cellular Tumor Antigen p53 Market Competitive Situation and Trends
2.7.1 Cellular Tumor Antigen p53 Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cellular Tumor Antigen p53 Players Market Share by Revenue
2.7.3 Global Cellular Tumor Antigen p53 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cellular Tumor Antigen p53 Retrospective Market Scenario by Region
3.1 Global Cellular Tumor Antigen p53 Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global Cellular Tumor Antigen p53 Global Cellular Tumor Antigen p53 Sales by Region: 2018-2034
3.2.1 Global Cellular Tumor Antigen p53 Sales by Region: 2018-2024
3.2.2 Global Cellular Tumor Antigen p53 Sales by Region: 2024-2034
3.3 Global Cellular Tumor Antigen p53 Global Cellular Tumor Antigen p53 Revenue by Region: 2018-2034
3.3.1 Global Cellular Tumor Antigen p53 Revenue by Region: 2018-2024
3.3.2 Global Cellular Tumor Antigen p53 Revenue by Region: 2024-2034
3.4 North America Cellular Tumor Antigen p53 Market Facts & Figures by Country
3.4.1 North America Cellular Tumor Antigen p53 Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America Cellular Tumor Antigen p53 Sales by Country (2018-2034)
3.4.3 North America Cellular Tumor Antigen p53 Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cellular Tumor Antigen p53 Market Facts & Figures by Country
3.5.1 Europe Cellular Tumor Antigen p53 Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe Cellular Tumor Antigen p53 Sales by Country (2018-2034)
3.5.3 Europe Cellular Tumor Antigen p53 Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cellular Tumor Antigen p53 Market Facts & Figures by Country
3.6.1 Asia Pacific Cellular Tumor Antigen p53 Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific Cellular Tumor Antigen p53 Sales by Country (2018-2034)
3.6.3 Asia Pacific Cellular Tumor Antigen p53 Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cellular Tumor Antigen p53 Market Facts & Figures by Country
3.7.1 Latin America Cellular Tumor Antigen p53 Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America Cellular Tumor Antigen p53 Sales by Country (2018-2034)
3.7.3 Latin America Cellular Tumor Antigen p53 Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cellular Tumor Antigen p53 Market Facts & Figures by Country
3.8.1 Middle East and Africa Cellular Tumor Antigen p53 Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa Cellular Tumor Antigen p53 Sales by Country (2018-2034)
3.8.3 Middle East and Africa Cellular Tumor Antigen p53 Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cellular Tumor Antigen p53 Sales by Type (2018-2034)
4.1.1 Global Cellular Tumor Antigen p53 Sales by Type (2018-2024)
4.1.2 Global Cellular Tumor Antigen p53 Sales by Type (2024-2034)
4.1.3 Global Cellular Tumor Antigen p53 Sales Market Share by Type (2018-2034)
4.2 Global Cellular Tumor Antigen p53 Revenue by Type (2018-2034)
4.2.1 Global Cellular Tumor Antigen p53 Revenue by Type (2018-2024)
4.2.2 Global Cellular Tumor Antigen p53 Revenue by Type (2024-2034)
4.2.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2018-2034)
4.3 Global Cellular Tumor Antigen p53 Price by Type (2018-2034)
5 Segment by Application
5.1 Global Cellular Tumor Antigen p53 Sales by Application (2018-2034)
5.1.1 Global Cellular Tumor Antigen p53 Sales by Application (2018-2024)
5.1.2 Global Cellular Tumor Antigen p53 Sales by Application (2024-2034)
5.1.3 Global Cellular Tumor Antigen p53 Sales Market Share by Application (2018-2034)
5.2 Global Cellular Tumor Antigen p53 Revenue by Application (2018-2034)
5.2.1 Global Cellular Tumor Antigen p53 Revenue by Application (2018-2024)
5.2.2 Global Cellular Tumor Antigen p53 Revenue by Application (2024-2034)
5.2.3 Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2018-2034)
5.3 Global Cellular Tumor Antigen p53 Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Advaxis, Inc.
6.1.1 Advaxis, Inc. Corporation Information
6.1.2 Advaxis, Inc. Description and Business Overview
6.1.3 Advaxis, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio
6.1.5 Advaxis, Inc. Recent Developments/Updates
6.2 American Gene Technologies International Inc.
6.2.1 American Gene Technologies International Inc. Corporation Information
6.2.2 American Gene Technologies International Inc. Description and Business Overview
6.2.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.2.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio
6.2.5 American Gene Technologies International Inc. Recent Developments/Updates
6.3 Aprea AB
6.3.1 Aprea AB Corporation Information
6.3.2 Aprea AB Description and Business Overview
6.3.3 Aprea AB Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Aprea AB Cellular Tumor Antigen p53 Product Portfolio
6.3.5 Aprea AB Recent Developments/Updates
6.4 Cellceutix Corporation
6.4.1 Cellceutix Corporation Corporation Information
6.4.2 Cellceutix Corporation Description and Business Overview
6.4.3 Cellceutix Corporation Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio
6.4.5 Cellceutix Corporation Recent Developments/Updates
6.5 Critical Outcome Technologies Inc.
6.5.1 Critical Outcome Technologies Inc. Corporation Information
6.5.2 Critical Outcome Technologies Inc. Description and Business Overview
6.5.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio
6.5.5 Critical Outcome Technologies Inc. Recent Developments/Updates
6.6 Eleos Inc.
6.6.1 Eleos Inc. Corporation Information
6.6.2 Eleos Inc. Description and Business Overview
6.6.3 Eleos Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio
6.6.5 Eleos Inc. Recent Developments/Updates
6.7 ORCA Therapeutics B.V.
6.6.1 ORCA Therapeutics B.V. Corporation Information
6.6.2 ORCA Therapeutics B.V. Description and Business Overview
6.6.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.4.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio
6.7.5 ORCA Therapeutics B.V. Recent Developments/Updates
6.8 OSE Pharma SA
6.8.1 OSE Pharma SA Corporation Information
6.8.2 OSE Pharma SA Description and Business Overview
6.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio
6.8.5 OSE Pharma SA Recent Developments/Updates
6.9 PCI Biotech Holding ASA
6.9.1 PCI Biotech Holding ASA Corporation Information
6.9.2 PCI Biotech Holding ASA Description and Business Overview
6.9.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.9.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio
6.9.5 PCI Biotech Holding ASA Recent Developments/Updates
6.10 Quark Pharmaceuticals, Inc.
6.10.1 Quark Pharmaceuticals, Inc. Corporation Information
6.10.2 Quark Pharmaceuticals, Inc. Description and Business Overview
6.10.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio
6.10.5 Quark Pharmaceuticals, Inc. Recent Developments/Updates
6.11 Stemline Therapeutics, Inc.
6.11.1 Stemline Therapeutics, Inc. Corporation Information
6.11.2 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Description and Business Overview
6.11.3 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio
6.11.5 Stemline Therapeutics, Inc. Recent Developments/Updates
6.12 Shenzen SiBiono GeneTech Co., Ltd.
6.12.1 Shenzen SiBiono GeneTech Co., Ltd. Corporation Information
6.12.2 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Description and Business Overview
6.12.3 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
6.12.5 Shenzen SiBiono GeneTech Co., Ltd. Recent Developments/Updates
6.13 SK Biopharmaceuticals Co., Ltd.
6.13.1 SK Biopharmaceuticals Co., Ltd. Corporation Information
6.13.2 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Description and Business Overview
6.13.3 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.13.4 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
6.13.5 SK Biopharmaceuticals Co., Ltd. Recent Developments/Updates
6.14 Tara Immuno-Oncology Therapeutics LLC
6.14.1 Tara Immuno-Oncology Therapeutics LLC Corporation Information
6.14.2 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Description and Business Overview
6.14.3 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio
6.14.5 Tara Immuno-Oncology Therapeutics LLC Recent Developments/Updates
6.15 Z53 Therapeutics, LLC
6.15.1 Z53 Therapeutics, LLC Corporation Information
6.15.2 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Description and Business Overview
6.15.3 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio
6.15.5 Z53 Therapeutics, LLC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cellular Tumor Antigen p53 Industry Chain Analysis
7.2 Cellular Tumor Antigen p53 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cellular Tumor Antigen p53 Production Mode & Process
7.4 Cellular Tumor Antigen p53 Sales and Marketing
7.4.1 Cellular Tumor Antigen p53 Sales Channels
7.4.2 Cellular Tumor Antigen p53 Distributors
7.5 Cellular Tumor Antigen p53 Customers
8 Cellular Tumor Antigen p53 Market Dynamics
8.1 Cellular Tumor Antigen p53 Industry Trends
8.2 Cellular Tumor Antigen p53 Market Drivers
8.3 Cellular Tumor Antigen p53 Market Challenges
8.4 Cellular Tumor Antigen p53 Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Cellular Tumor Antigen p53 Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Cellular Tumor Antigen p53 Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Cellular Tumor Antigen p53 Market Competitive Situation by Manufacturers in 2022
Table 4. Global Cellular Tumor Antigen p53 Sales (K Pcs) of Key Manufacturers (2018-2024)
Table 5. Global Cellular Tumor Antigen p53 Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Cellular Tumor Antigen p53 Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Cellular Tumor Antigen p53 Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Cellular Tumor Antigen p53 Average Price (USD/Pcs) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Cellular Tumor Antigen p53, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Cellular Tumor Antigen p53, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cellular Tumor Antigen p53, Product Type & Application
Table 12. Global Key Manufacturers of Cellular Tumor Antigen p53, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cellular Tumor Antigen p53 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cellular Tumor Antigen p53 as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cellular Tumor Antigen p53 Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global Cellular Tumor Antigen p53 Sales by Region (2018-2024) & (K Pcs)
Table 18. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2018-2024)
Table 19. Global Cellular Tumor Antigen p53 Sales by Region (2024-2034) & (K Pcs)
Table 20. Global Cellular Tumor Antigen p53 Sales Market Share by Region (2024-2034)
Table 21. Global Cellular Tumor Antigen p53 Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2018-2024)
Table 23. Global Cellular Tumor Antigen p53 Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Cellular Tumor Antigen p53 Revenue Market Share by Region (2024-2034)
Table 25. North America Cellular Tumor Antigen p53 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America Cellular Tumor Antigen p53 Sales by Country (2018-2024) & (K Pcs)
Table 27. North America Cellular Tumor Antigen p53 Sales by Country (2024-2034) & (K Pcs)
Table 28. North America Cellular Tumor Antigen p53 Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Cellular Tumor Antigen p53 Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Cellular Tumor Antigen p53 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Cellular Tumor Antigen p53 Sales by Country (2018-2024) & (K Pcs)
Table 32. Europe Cellular Tumor Antigen p53 Sales by Country (2024-2034) & (K Pcs)
Table 33. Europe Cellular Tumor Antigen p53 Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Cellular Tumor Antigen p53 Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Cellular Tumor Antigen p53 Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Cellular Tumor Antigen p53 Sales by Region (2018-2024) & (K Pcs)
Table 37. Asia Pacific Cellular Tumor Antigen p53 Sales by Region (2024-2034) & (K Pcs)
Table 38. Asia Pacific Cellular Tumor Antigen p53 Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Cellular Tumor Antigen p53 Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Cellular Tumor Antigen p53 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Cellular Tumor Antigen p53 Sales by Country (2018-2024) & (K Pcs)
Table 42. Latin America Cellular Tumor Antigen p53 Sales by Country (2024-2034) & (K Pcs)
Table 43. Latin America Cellular Tumor Antigen p53 Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Cellular Tumor Antigen p53 Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Cellular Tumor Antigen p53 Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Cellular Tumor Antigen p53 Sales by Country (2018-2024) & (K Pcs)
Table 47. Middle East & Africa Cellular Tumor Antigen p53 Sales by Country (2024-2034) & (K Pcs)
Table 48. Middle East & Africa Cellular Tumor Antigen p53 Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Cellular Tumor Antigen p53 Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Cellular Tumor Antigen p53 Sales (K Pcs) by Type (2018-2024)
Table 51. Global Cellular Tumor Antigen p53 Sales (K Pcs) by Type (2024-2034)
Table 52. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2018-2024)
Table 53. Global Cellular Tumor Antigen p53 Sales Market Share by Type (2024-2034)
Table 54. Global Cellular Tumor Antigen p53 Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Cellular Tumor Antigen p53 Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2018-2024)
Table 57. Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2024-2034)
Table 58. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Type (2018-2024)
Table 59. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Type (2024-2034)
Table 60. Global Cellular Tumor Antigen p53 Sales (K Pcs) by Application (2018-2024)
Table 61. Global Cellular Tumor Antigen p53 Sales (K Pcs) by Application (2024-2034)
Table 62. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2018-2024)
Table 63. Global Cellular Tumor Antigen p53 Sales Market Share by Application (2024-2034)
Table 64. Global Cellular Tumor Antigen p53 Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Cellular Tumor Antigen p53 Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2018-2024)
Table 67. Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2024-2034)
Table 68. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Application (2018-2024)
Table 69. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Application (2024-2034)
Table 70. Advaxis, Inc. Corporation Information
Table 71. Advaxis, Inc. Description and Business Overview
Table 72. Advaxis, Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 73. Advaxis, Inc. Cellular Tumor Antigen p53 Product
Table 74. Advaxis, Inc. Recent Developments/Updates
Table 75. American Gene Technologies International Inc. Corporation Information
Table 76. American Gene Technologies International Inc. Description and Business Overview
Table 77. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 78. American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product
Table 79. American Gene Technologies International Inc. Recent Developments/Updates
Table 80. Aprea AB Corporation Information
Table 81. Aprea AB Description and Business Overview
Table 82. Aprea AB Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 83. Aprea AB Cellular Tumor Antigen p53 Product
Table 84. Aprea AB Recent Developments/Updates
Table 85. Cellceutix Corporation Corporation Information
Table 86. Cellceutix Corporation Description and Business Overview
Table 87. Cellceutix Corporation Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 88. Cellceutix Corporation Cellular Tumor Antigen p53 Product
Table 89. Cellceutix Corporation Recent Developments/Updates
Table 90. Critical Outcome Technologies Inc. Corporation Information
Table 91. Critical Outcome Technologies Inc. Description and Business Overview
Table 92. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 93. Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product
Table 94. Critical Outcome Technologies Inc. Recent Developments/Updates
Table 95. Eleos Inc. Corporation Information
Table 96. Eleos Inc. Description and Business Overview
Table 97. Eleos Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 98. Eleos Inc. Cellular Tumor Antigen p53 Product
Table 99. Eleos Inc. Recent Developments/Updates
Table 100. ORCA Therapeutics B.V. Corporation Information
Table 101. ORCA Therapeutics B.V. Description and Business Overview
Table 102. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 103. ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product
Table 104. ORCA Therapeutics B.V. Recent Developments/Updates
Table 105. OSE Pharma SA Corporation Information
Table 106. OSE Pharma SA Description and Business Overview
Table 107. OSE Pharma SA Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 108. OSE Pharma SA Cellular Tumor Antigen p53 Product
Table 109. OSE Pharma SA Recent Developments/Updates
Table 110. PCI Biotech Holding ASA Corporation Information
Table 111. PCI Biotech Holding ASA Description and Business Overview
Table 112. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product
Table 114. PCI Biotech Holding ASA Recent Developments/Updates
Table 115. Quark Pharmaceuticals, Inc. Corporation Information
Table 116. Quark Pharmaceuticals, Inc. Description and Business Overview
Table 117. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product
Table 119. Quark Pharmaceuticals, Inc. Recent Developments/Updates
Table 120. Stemline Therapeutics, Inc. Corporation Information
Table 121. Stemline Therapeutics, Inc. Description and Business Overview
Table 122. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product
Table 124. Stemline Therapeutics, Inc. Recent Developments/Updates
Table 125. Shenzen SiBiono GeneTech Co., Ltd. Corporation Information
Table 126. Shenzen SiBiono GeneTech Co., Ltd. Description and Business Overview
Table 127. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product
Table 129. Shenzen SiBiono GeneTech Co., Ltd. Recent Developments/Updates
Table 130. SK Biopharmaceuticals Co., Ltd. Corporation Information
Table 131. SK Biopharmaceuticals Co., Ltd. Description and Business Overview
Table 132. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product
Table 134. SK Biopharmaceuticals Co., Ltd. Recent Developments/Updates
Table 135. Tara Immuno-Oncology Therapeutics LLC Corporation Information
Table 136. Tara Immuno-Oncology Therapeutics LLC Description and Business Overview
Table 137. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product
Table 139. Tara Immuno-Oncology Therapeutics LLC Recent Developments/Updates
Table 140. Z53 Therapeutics, LLC Corporation Information
Table 141. Z53 Therapeutics, LLC Description and Business Overview
Table 142. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 143. Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product
Table 144. Z53 Therapeutics, LLC Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Cellular Tumor Antigen p53 Distributors List
Table 148. Cellular Tumor Antigen p53 Customers List
Table 149. Cellular Tumor Antigen p53 Market Trends
Table 150. Cellular Tumor Antigen p53 Market Drivers
Table 151. Cellular Tumor Antigen p53 Market Challenges
Table 152. Cellular Tumor Antigen p53 Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cellular Tumor Antigen p53
Figure 2. Global Cellular Tumor Antigen p53 Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Cellular Tumor Antigen p53 Market Share by Type in 2022 & 2034
Figure 4. COTI-2 Product Picture
Figure 5. D-12PGJ3 Product Picture
Figure 6. APR-246 Product Picture
Figure 7. ATRN-502 Product Picture
Figure 8. Cenersen Sodium Product Picture
Figure 9. MJ-05 Product Picture
Figure 10. MX-225 Product Picture
Figure 11. Others Product Picture
Figure 12. Global Cellular Tumor Antigen p53 Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 13. Global Cellular Tumor Antigen p53 Market Share by Application in 2022 & 2034
Figure 14. Ovarian Cancer
Figure 15. Prostate Cancer
Figure 16. Brain Cancer
Figure 17. Others
Figure 18. Global Cellular Tumor Antigen p53 Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Cellular Tumor Antigen p53 Market Size (2018-2034) & (US$ Million)
Figure 20. Global Cellular Tumor Antigen p53 Sales (2018-2034) & (K Pcs)
Figure 21. Global Cellular Tumor Antigen p53 Average Price (USD/Pcs) & (2018-2034)
Figure 22. Cellular Tumor Antigen p53 Report Years Considered
Figure 23. Cellular Tumor Antigen p53 Sales Share by Manufacturers in 2022
Figure 24. Global Cellular Tumor Antigen p53 Revenue Share by Manufacturers in 2022
Figure 25. The Global 5 and 10 Largest Cellular Tumor Antigen p53 Players: Market Share by Revenue in 2022
Figure 26. Cellular Tumor Antigen p53 Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 27. Global Cellular Tumor Antigen p53 Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 28. North America Cellular Tumor Antigen p53 Sales Market Share by Country (2018-2034)
Figure 29. North America Cellular Tumor Antigen p53 Revenue Market Share by Country (2018-2034)
Figure 30. U.S. Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Canada Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Europe Cellular Tumor Antigen p53 Sales Market Share by Country (2018-2034)
Figure 33. Europe Cellular Tumor Antigen p53 Revenue Market Share by Country (2018-2034)
Figure 34. Germany Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. France Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. U.K. Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Italy Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Russia Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Cellular Tumor Antigen p53 Sales Market Share by Region (2018-2034)
Figure 40. Asia Pacific Cellular Tumor Antigen p53 Revenue Market Share by Region (2018-2034)
Figure 41. China Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Japan Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. South Korea Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. India Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Australia Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Taiwan Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Indonesia Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Thailand Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Malaysia Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Philippines Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Latin America Cellular Tumor Antigen p53 Sales Market Share by Country (2018-2034)
Figure 52. Latin America Cellular Tumor Antigen p53 Revenue Market Share by Country (2018-2034)
Figure 53. Mexico Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. Brazil Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Argentina Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Middle East & Africa Cellular Tumor Antigen p53 Sales Market Share by Country (2018-2034)
Figure 57. Middle East & Africa Cellular Tumor Antigen p53 Revenue Market Share by Country (2018-2034)
Figure 58. Turkey Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 59. Saudi Arabia Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 60. U.A.E Cellular Tumor Antigen p53 Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 61. Global Sales Market Share of Cellular Tumor Antigen p53 by Type (2018-2034)
Figure 62. Global Revenue Market Share of Cellular Tumor Antigen p53 by Type (2018-2034)
Figure 63. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Type (2018-2034)
Figure 64. Global Sales Market Share of Cellular Tumor Antigen p53 by Application (2018-2034)
Figure 65. Global Revenue Market Share of Cellular Tumor Antigen p53 by Application (2018-2034)
Figure 66. Global Cellular Tumor Antigen p53 Price (USD/Pcs) by Application (2018-2034)
Figure 67. Cellular Tumor Antigen p53 Value Chain
Figure 68. Cellular Tumor Antigen p53 Production Process
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Distributors Profiles
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed